• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Introduction

Dyslipidemia, characterized by abnormal levels of lipids in the blood, is a major modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD). While statins are the cornerstone of lipid-lowering therapy, a significant number of patients cannot tolerate high-intensity statins or present with a mixed dyslipidemia profile—specifically high triglycerides and low high-density lipoprotein (HDL) cholesterol—that may require adjunctive therapy. This case study examines the role of Lopid (gemfibrozil), a fibrate medication, in the management of such patients, exploring its efficacy, safety profile, and place in modern therapeutic regimens.

Patient Profile and Presentation

Mr. Johnson, a 58-year-old male with a history of Type 2 diabetes (well-controlled with metformin) and hypertension, presented for a routine follow-up. He had been on atorvastatin 20 mg daily for five years for primary prevention but reported persistent myalgia, leading to poor adherence. Baseline labs revealed a lipid panel with Total Cholesterol: 210 mg/dL, LDL-C: 110 mg/dL, HDL-C: 32 mg/dL, and markedly elevated Triglycerides: 480 mg/dL. His non-HDL cholesterol was high at 178 mg/dL. Given his statin intolerance and the predominant pattern of hypertriglyceridemia with low HDL-C, his cardiologist considered a therapeutic shift.

Therapeutic Decision: Initiating Lopid

After a shared decision-making discussion, the decision was made to discontinue atorvastatin and initiate Lopid (gemfibrozil) 600 mg twice daily. This choice was guided by several factors:

1. 
   
2. Mechanism of Action: Gemfibrozil is a fibrate that activates peroxisome proliferator-activated receptor alpha (PPAR-α). This primarily stimulates lipoprotein lipase, enhancing the catabolism of triglyceride-rich VLDL particles, and modestly increases HDL-C synthesis.
   
3. Evidence Base: The Helsinki Heart Study and the VA-HIT trial demonstrated that gemfibrozil significantly reduced major coronary events in patients with dyslipidemia, particularly those with high triglycerides and low HDL-C, independent of major LDL-C lowering.
   
4. Patient-Specific Factors: The therapy directly targeted Mr. Johnson's most abnormal lipid parameters. A plan was made to re-check lipids in 8 weeks and monitor for efficacy and adverse effects.
   

Treatment Course and Monitoring

At the 8-week follow-up, Mr. Johnson reported no muscle pain and good medication tolerance. Repeat lipid panel showed a dramatic improvement: Triglycerides: 180 mg/dL (a 62.5% reduction), HDL-C: 38 mg/dL (an 18% increase). However, his LDL-C had increased to 125 mg/dL, a known potential effect of fibrates in some patients with high baseline triglycerides, as they catalyze the conversion of VLDL remnants to LDL particles. His non-HDL-C improved to 142 mg/dL. Liver function tests (LFTs) and creatinine were within normal limits. The focus remained on the significant reduction in atherogenic triglyceride-rich remnants and the improved overall profile.

Long-Term Management and Challenges

Over the next year, Mr. Johnson's triglycerides remained well-controlled (consistently under 200 mg/dL) on gemfibrozil monotherapy. However, given his diabetic status, his calculated 10-year ASCVD risk remained in the intermediate zone. The residual elevation in LDL-C and non-HDL-C was a concern. Re-challenge with a low-dose, hydrophilic statin (pravastatin 20 mg) was cautiously attempted to address this, with strict monitoring for myopathy—a known risk when combining fibrates (especially gemfibrozil) with statins due to drug-drug interactions involving CYP450 and glucuronidation pathways. The combination was successful without adverse effects, yielding an optimal final lipid profile: LDL-C: 85 mg/dL, TG: Asendin (https://Labovienat.com) 160 mg/dL, HDL-C: 42 mg/dL.

Discussion: Efficacy, Safety, and Modern Context

Mr. Johnson's case illustrates several key points about Lopid (gemfibrozil):

• 
  
• Efficacy in Mixed Dyslipidemia: Gemfibrozil is highly effective in reducing triglyceride levels and, to a lesser degree, raising HDL-C. It is most beneficial for patients with a specific atherogenic dyslipidemia phenotype.
  
• Safety and Monitoring: While generally well-tolerated, gemfibrozil requires monitoring. Key risks include:
  
  • 
    
  • Myopathy/Rhabdomyolysis: Risk increases significantly when combined with statins, particularly with CYP450-metabolized statins like lovastatin or simvastatin. Using pravastatin or rosuvastatin with caution is preferred if combination therapy is necessary.
    
  • Hepatic Effects: Transaminase elevations can occur; periodic LFT monitoring is recommended.
    
  • Renal Impairment & Gallstones: Use with caution in renal dysfunction, and be aware of a potential increased risk of cholelithiasis.
    
  
  
  
• Place in Therapy: In the contemporary era, gemfibrozil's role has been nuanced. While newer fibrates like fenofibrate have a more favorable drug-interaction profile with statins, gemfibrozil remains a potent, cost-effective option for statin-intolerant patients with severe hypertriglyceridemia. Its event reduction benefit is well-established in specific populations.
  
• Holistic Management: As seen in this case, pharmacotherapy must be coupled with ongoing lifestyle counseling. Mr. Johnson also adhered to a Mediterranean-style diet and regular aerobic exercise, which contributed to his positive outcomes.
  

Conclusion

The case of Mr. Johnson underscores that Lopid (gemfibrozil) remains a valuable therapeutic agent in the cardiologist's armamentarium. Its primary strength lies in managing high-risk patients with mixed dyslipidemia—specifically elevated triglycerides and low HDL cholesterol—particularly when statin intolerance is present. Successful treatment requires careful patient selection, awareness of its distinct safety profile (especially regarding drug interactions and myopathy risk), and a commitment to ongoing monitoring. While often not a first-line monotherapy, it serves as a crucial tool for achieving comprehensive lipid control, either alone or in carefully managed combination regimens, thereby reducing the residual cardiovascular risk in a challenging patient population.